
Z Squared (ZSQR) had the highest return since November 30, 2024 and on December 31, 2024 by a US stock, returning 96.4%.
| ASSET | % RETURN |
|---|---|
Z Squared (ZSQR) | 96.43% |
Twin Vee Powercats (VEEE) | 48.65% |
Tvardi Therapeutics (TVRD) | 46.41% |
Abits (ABTS) | 43.9% |
NRX Pharmaceuticals (NRXP) | 41.94% |
Kestrel (KG) | 37.4% |
Bristol-Myers Squibb Company Ce (CELG.RI) | 34.99% |
Scully Royalty (SRL) | 31.77% |
Aethlon Medical (AEMD) | 29.77% |
Park Ha Biological Technology (BYAH) | 28.11% |
VivoSim Labs (VIVS) | 27.78% |
Kandi Technologies (KNDI) | 27.66% |
ClearOne (CLRO) | 23.81% |
Revelation Biosciences (REVB) | 23.64% |
JX Luxventure (JXG) | 23% |
Beeline (BLNE) | 22.99% |
reAlpha Tech Corp Common Stock (AIRE) | 22.98% |
Precigen (PGEN) | 20.43% |
Jowell Global (JWEL) | 19.23% |
Healthcare Triangle (HCTI) | 19.23% |
Aware (AWRE) | 18.9% |
Adlai Nortye Ltd American Depositary Shares (ANL) | 18.81% |
Akari Therapeutics (AKTX) | 18.45% |
XTL Biopharmaceuticals Ltd ADR (XTLB) | 17.78% |
XMax (XMAX) | 17.54% |